Version history

{
  "session_id": "sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "propose",
  "content": "Based on the glial ketone shunt hypothesis and astrocyte-neuron metabolic interactions in neurodegeneration, here are 7 novel therapeutic hypotheses:\n\n## Hypothesis 1: Temporal Metabolic Window Therapy\n**Description:** There exists a critical therapeutic window early in neurodegeneration where astrocytic ketone production is declining but neurons retain ketone oxidation capacity. Targeted ketone supplementation during this specific phase could restore metabolic coupling and prevent irreversible neuronal damage.\n\n**Target gene/protein:** HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) - key enzyme in ketone synthesis\n\n**Supporting evidence:** The glial ketone shunt hypothesis suggests astrocytes can switch from glucose to ketone metabolism, but temporal dynamics remain unexplored as noted in the gap.\n\n**Confidence:** 0.75\n\n## Hypothesis 2: Astrocyte Metabolic Memory Reprogramming\n**Description:** Astrocytes develop pathological \"metabolic memory\" during neurodegeneration, persistently favoring glycolysis over ketogenesis even when glucose is limiting. Epigenetic modulators targeting metabolic gene promoters could reset astrocytic fuel preference and restore neuroprotective ketone supply.\n\n**Target gene/protein:** SIRT1 (Sirtuin 1) - epigenetic regulator of metabolic genes\n\n**Supporting evidence:** The cell-type specificity mentioned in the gap suggests astrocytes undergo distinct metabolic reprogramming that could involve epigenetic mechanisms.\n\n**Confidence:** 0.68\n\n## Hypothesis 3: Neuron-Astrocyte Metabolic Mismatch Syndrome\n**Description:** Progressive neurodegeneration involves a temporal mismatch where neurons upregulate ketone transporter expression (MCT2) while astrocytes simultaneously lose ketogenesis capacity. Combination therapy targeting both astrocytic ketone production enhancement and neuronal glucose uptake could compensate for this mismatch.\n\n**Target gene/protein:** SLC16A7 (MCT2 monocarboxylate transporter) and GLUT3 co-targeting\n\n**Supporting evidence:** The gap emphasizes temporal dynamics and cell-type specificity, suggesting coordinated but misaligned changes between cell types.\n\n**Confidence:** 0.72\n\n## Hypothesis 4: Mitochondrial Coupling Restoration Therapy\n**Description:** Astrocyte mitochondrial dysfunction precedes neuronal metabolic failure in neurodegeneration by disrupting the ketone supply chain. Direct mitochondrial transplantation or mitochondrial biogenesis enhancers specifically in astrocytes could restore the metabolic support network for neurons.\n\n**Target gene/protein:** PGC1α (PPARGC1A) - master regulator of mitochondrial biogenesis\n\n**Supporting evidence:** The glial ketone shunt requires functional astrocytic mitochondria, and metabolic reprogramming likely involves mitochondrial dysfunction.\n\n**Confidence:** 0.71\n\n## Hypothesis 5: Astrocyte Metabolic State Biosensor Therapy\n**Description:** Real-time monitoring of astrocytic ketone production using engineered biosensors could guide precision timing of metabolic interventions. This approach would identify the optimal therapeutic window when astrocytes are metabolically responsive but neurons haven't yet lost ketone utilization capacity.\n\n**Target gene/protein:** Engineered FRET-based ketone sensors targeting astrocyte-specific expression\n\n**Supporting evidence:** The gap specifically mentions that \"temporal dynamics remain unexplored\" and questions about \"when metabolic interventions might be most effective.\"\n\n**Confidence:** 0.65\n\n## Hypothesis 6: Ketone-Lactate Metabolic Switch Therapy\n**Description:** During neurodegeneration, astrocytes pathologically shift from producing neuroprotective ketones to potentially harmful lactate accumulation. Selective inhibition of lactate dehydrogenase in astrocytes while enhancing ketogenesis could redirect metabolic flux toward neuroprotection.\n\n**Target gene/protein:** LDHA (Lactate dehydrogenase A) inhibition combined with HMGCS2 activation\n\n**Supporting evidence:** The metabolic reprogramming mentioned in the gap likely involves shifts in major metabolic pathways beyond just ketogenesis.\n\n**Confidence:** 0.73\n\n## Hypothesis 7: Astrocyte Fuel Preference Pharmacogenomics\n**Description:** Genetic variants in astrocytic metabolic enzymes determine individual susceptibility to neurodegeneration and response to ketogenic therapies. Personalized metabolic interventions based on astrocyte-specific genetic profiles could optimize therapeutic timing and efficacy.\n\n**Target gene/protein:** Multiple SNPs in HMGCS2, OXCT1, and SLC16A1 for pharmacogenomic profiling\n\n**Supporting evidence:** The cell-type specificity mentioned in the gap suggests that astrocytic responses may vary between individuals, potentially due to genetic factors.\n\n**Confidence:** 0.69\n\nThese hypotheses address the critical knowledge gap by proposing mechanisms for how astrocyte-neuron metabolic interactions change temporally during neurodegeneration and suggest specific intervention strategies targeting different aspects of this metabolic coupling dysfunction.",
  "tokens_used": "1262",
  "persona_id": "persona-theorist"
}